Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Change in Account Payables (2020 - 2025)

Maravai Lifesciences Holdings has reported Change in Account Payables over the past 6 years, most recently at -$5.5 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$5.5 million for Q4 2025, down 344.68% from a year ago — trailing twelve months through Dec 2025 was -$7.3 million (down 1116.18% YoY), and the annual figure for FY2025 was -$7.3 million, down 1116.18%.
  • Change in Account Payables for Q4 2025 was -$5.5 million at Maravai Lifesciences Holdings, down from -$2.9 million in the prior quarter.
  • Over the last five years, Change in Account Payables for MRVI hit a ceiling of $4.6 million in Q2 2024 and a floor of -$5.5 million in Q4 2025.
  • Median Change in Account Payables over the past 5 years was $712000.0 (2023), compared with a mean of -$112100.0.
  • Biggest five-year swings in Change in Account Payables: soared 13223.53% in 2021 and later tumbled 1466.81% in 2024.
  • Maravai Lifesciences Holdings' Change in Account Payables stood at -$867000.0 in 2021, then plummeted by 300.0% to -$3.5 million in 2022, then skyrocketed by 147.84% to $1.7 million in 2023, then skyrocketed by 35.86% to $2.3 million in 2024, then tumbled by 344.68% to -$5.5 million in 2025.
  • The last three reported values for Change in Account Payables were -$5.5 million (Q4 2025), -$2.9 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.